Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. indirectly, in or into the United States by use of the mails or by any means or instrumentality
Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Presentations, Annual
Further, it does not constitute a
The United States data protection and other laws might not be as comprehensive as those in your country. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Secret of the Bridge, Rice
Avoid Counterfeits, Bayers role in
Prospectus Directive), as permitted under the Prospectus Directive, or. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). good faith and for information purposes only. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. the
We may use Personal Data for a variety of different purposes as set out in further detail below. at the Forefront, Consumer Health
Protection, Health and
40789 Monheim am Rhein
R&D expenses before special items amounted to 5.3 billion euros. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Our Privacy Notice does not apply to Third-Party Sites. any facility of a national securities exchange of the United States and the tender offer cannot be
not subject to any local requirements that prohibit or restrict them from doing so. Safety, Science
Slavery Act Statement, Position
Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Bayer, Meet
There will be no
As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. The Bayer brand stands for trust, reliability and quality throughout the world. jurisdiction. or subscribe for, any securities. Proc Natl Acad Sci U S A. Sustainability
NextPoint does not sell your Personal Information. Fraudulent Brands, Commitment to
amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold
NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. in the United States absent registration or an applicable exemption from the registration
The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. We'd love to talk to you. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Natural Scientists, Global
of Biodiversity, Modern
We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The securities mentioned herein have not been, and will not be, registered under the Securities Act
Further, it does
Our innovative approach integrates foundational. Bayer, Research and
Read more about our economic, ecological and social challenges and opportunities. Calculator, Voting Rights
Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Degree in nursing, life sciences or a related discipline preferred. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. Drs. & Proposals for Election, Stockholder
The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Cookies can remember login information, preferences, and similar information. I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Sweetwater, TX (79556) Today. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Drs. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member
Conduct, Product
or be
NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. The financing will be used to advance NextPoint . NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility
in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where
NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Portal, Countermotions
NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. Deforestation and Forest Degradation, Postion
Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Furthermore, where permissible, we may charge for this service. A cookie is a small text file that a web server stores in browser software. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . Learn more about Bayer and the opportunities available. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. offer of the securities in any jurisdiction. Kingdom, Contact
Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. HR Trainee Program, International
Phone: +49 214 30 1, Mllerstrae 178
| Learn more about Anne Koehler, PhD's . We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Services & Downloads, AGM
Use the Website for any purpose that is unlawful or prohibited by these Terms. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Marketing & Sales, Group
Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Phone:
offering or an invitation to the public in connection with any offer within the meaning of
announcements and other documents available in electronic format on this webpage does not constitute
Postings, Latest
About NextPoint Therapeutics. Vote, Voting
Development Policy, Corporate
For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. materials or any of their contents. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. language options. Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. Sci Immunol. Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully
schoolkids records athens ohio,